Search - tctmd.com

Displaying 1 - 20 of 33

Sort: Relevancy | Date

Presentation TCT 2016

Case Introduction: What Device(s) to Choose in a Patient With NSTE-ACS?

Presenter: George D. Dangas, Fabio Felice Tarantino, Massimo Fineschi

November 01, 2016

Presentation TCT 2016

Case Conclusion: How Did We Treat Our Patient?

Presenter: Roxana Mehran, Ferdinando Varbella, Alberto Menozzi

November 01, 2016

Presentation TCT 2016

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

Presenter: Roxana Mehran, Ferdinando Varbella, Dominick J. Angiolillo

November 01, 2016

Presentation TCT 2016

To Pretreat or Not to Pretreat? The DUBIUS Trial

Presenter: Roxana Mehran, Ferdinando Varbella, Giuseppe Tarantini

November 01, 2016

Presentation TCT 2016

Case Introduction: An Elderly Patient With NSTE-ACS

Presenter: Roxana Mehran, Ferdinando Varbella, Alberto Menozzi

November 01, 2016

Presentation TCT 2016

Unmet Needs and Data Gaps for Pharmacotherapy in Patients With NSTE-ACS

Presenter: C. Michael Gibson, Daniel I. Simon, Glenn N. Levine

October 30, 2016

Presentation TCT 2016

Acute Coronary Syndromes: NSTE-ACS

Presenter: Peter Barlis, Grzegorz L. Kaluza, Ziad A. Ali

October 29, 2016

Presentation

Spontaneous MI After NSTE ACS Managed Without Revascularization

Presenter: Renato Lopes

March 15, 2016

Presentation

Does Stable NSTE-ACS Require Admission to Coronary Care Units?

Presenter: S. van Diepen

January 27, 2016

Presentation TCT 2015

NSTE-ACS Case Presentation: From Presentation Through Discharge

Presenter: Ajay J. Kirtane, Gary S. Mintz, Manish A. Parikh, Bo Xu, Qi Zhang

October 11, 2015

Presentation TCT 2015

NSTE-ACS: Risk Stratification and Treatment

Presenter: Emmanouil S. Brilakis, Dmitriy N. Feldman

October 11, 2015

Presentation

Impact of Anticoagulation Regimen Prior toRevascularization in Patients With NSTE-ACS

Presenter: Tobias Geisler

September 18, 2015

Presentation

RITA 3: 10-Year Mortality Outcome of Routine Invasive vs Selective Invasive Strategy in NSTE-ACS

Presenter: Robert A. Henderson

July 29, 2015

Presentation

Effect of an Invasive Strategy on Outcome in Patients ≥ 75 Years of Age With NSTE-ACS

Presenter: Gennaro Galasso

January 11, 2015

Presentation AHA 2014

Efficacy and safety of vorapaxar in NSTE ACS patients undergoing non-cardiac surgery

Presenter: S. van Diepen

November 16, 2014

Presentation

Reappraisal of Thienopyridine Pretreatmentin NSTE-ACS Patients

Presenter: A. Bellemain-Appaix

November 06, 2014

Presentation TCT 2014

Role of Intravascular Imaging in NSTE-ACS and STEMI

Presenter: Nils Johnson, Bernhard Witzenbichler, Michel R. Le May, Fernando Alfonso

September 16, 2014

Presentation TCT 2014

Role of FFR, IMR, and Other Physiologic Measures in NSTE-ACS and STEMI

Presenter: Nils Johnson, Bernhard Witzenbichler, Michel R. Le May, Colin Berry

September 16, 2014

Presentation TCT 2014

Preloading P2Y12 Antagonists in NSTE-ACS and STEMI: Safe and Effective? What Regimens?

Presenter: Dominick J. Angiolillo

September 13, 2014

Presentation TCT 2014

NSTE-ACS: Risk Stratification and Treatment

Presenter: Emmanouil S. Brilakis, Dmitriy N. Feldman

September 13, 2014

Advertisement

Case Introduction: What Device(s) to Choose in a Patient With NSTE-ACS?

Case Conclusion: How Did We Treat Our Patient?

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

To Pretreat or Not to Pretreat? The DUBIUS Trial

Case Introduction: An Elderly Patient With NSTE-ACS

Unmet Needs and Data Gaps for Pharmacotherapy in Patients With NSTE-ACS

Acute Coronary Syndromes: NSTE-ACS

Spontaneous MI After NSTE ACS Managed Without Revascularization

Does Stable NSTE-ACS Require Admission to Coronary Care Units?

NSTE-ACS Case Presentation: From Presentation Through Discharge

NSTE-ACS: Risk Stratification and Treatment

Impact of Anticoagulation Regimen Prior toRevascularization in Patients With NSTE-ACS

RITA 3: 10-Year Mortality Outcome of Routine Invasive vs Selective Invasive Strategy in NSTE-ACS

Effect of an Invasive Strategy on Outcome in Patients ≥ 75 Years of Age With NSTE-ACS

Efficacy and safety of vorapaxar in NSTE ACS patients undergoing non-cardiac surgery

Reappraisal of Thienopyridine Pretreatmentin NSTE-ACS Patients

Role of Intravascular Imaging in NSTE-ACS and STEMI

Role of FFR, IMR, and Other Physiologic Measures in NSTE-ACS and STEMI

Preloading P2Y12 Antagonists in NSTE-ACS and STEMI: Safe and Effective? What Regimens?

NSTE-ACS: Risk Stratification and Treatment

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content